American Journal of Kidney Diseases
Volume 53, Issue 3 , Pages 550-554 , March 2009

Kidney Involvement in Multicentric Castleman Disease

  • Sumeet Suneja, MD

      Affiliations

    • Department of Medicine, University Health Network, University of Toronto, Canada
    • ,
  • Mala Chidambaram, MD

      Affiliations

    • Department of Medicine, University Health Network, University of Toronto, Canada
    • ,
  • Andrew M. Herzenberg, MD

      Affiliations

    • Department of Pathology, University Health Network, University of Toronto, Canada
    • ,
  • Joanne M. Bargman, MD

      Affiliations

    • Department of Medicine, University Health Network, University of Toronto, Canada
    • Corresponding Author InformationAddress correspondence to Joanne M. Bargman, MD, Toronto General Hospital, 200 Elizabeth St, 8N-840, Toronto, Ontario M5G 2C4, Canada

Received 13 March 2008 ,Accepted 14 August 2008.

References 

  1. Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases (Part 2: Pathogenesis, Castleman's disease, and pleural effusion lymphoma). Lancet Infect Dis. 2002;2:344–352
  2. Shahidi H, Myers JL, Kvale PA. Castleman's disease. Mayo Clin Proc. 1995;70:969–977
  3. Montoli A, Minola E, Stabile F, et al. End-stage\failure from renal amyloidosis of the AA type associated with giant lymph node hyperplasia (Castleman's disease). Am J Nephrol. 1995;15:142–146
  4. Ruggieri G, Barsotti P, Copppola G, et al. Membranous nephropathy associated with giant lymph node hyperplasia. Am J Nephrol. 1990;10:323–328
  5. Seida A, Wada J, Morita Y, et al. Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion: Does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury?. Am J Kidney Dis. 2004;43:E3–E9
  6. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: From basic science to medicine. Arthritis Res. 2002;4(suppl 3):S233–S242
  7. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999;130:461–470
  8. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer. 1956;9:822–830
  9. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29:670–683
  10. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95:1406–1412
  11. Hsu SM, Waldron JA, Xie SS, et al. Expression of interleukin-6 in Castleman's disease. Hum Pathol. 1993;24:833–839
  12. Chadburn A, Cesarman E, Nador RG, et al. Kaposi's sarcoma-associated herpesvirus sequences in benign lymphoid proliferations not associated with human immunodeficiency virus. Cancer. 1997;80:788–797
  13. McCarty MJ, Vukelja SJ, Banks PM, et al. Angiofollicular lymph node hyperplasia (Castleman's disease). Cancer Treat Rev. 1995;21:291–310
  14. Frizzera G. Castleman's disease and related disorders. Semin Diagn Pathol. 1988;5:346–364
  15. Chan T, Cheng IKP, Wong K, et al. Resolution of membranoproliferative glomerulonephritis complicating angiofollicular lymph node hyperplasia (Castleman's disease). Nephron. 1993;65:628–632
  16. Tsukamoto Y, Hanada N, Nomura Y, et al. Rapidly progressive renal failure associated with angiofollicular lymph node hyperplasia. Am J Nephrol. 1991;11:430–436
  17. Summerfield GP, Taylor W, Bellingham AJ, et al. Hyaline-vascular variant of angiofollicular lymph node hyperplasia with systemic manifestation and response to corticosteroids. J Clin Pathol. 1983;36:1005–1011
  18. Couch WD. Giant lymph node hyperplasia associated with thrombotic thrombocytopenic purpura. Am J Clin Pathol. 1980;74:340–344
  19. Lajoie G, Kumar S, Min K, et al. Renal thrombotic microangiopathy associated with multicentric Castleman's disease. Am J Surg Pathol. 1995;19:1021–1028
  20. Jones CH, Will EJ. Angiofollicular lymph node hyperplasia, accelerated hypertension, and acute renal failure: A case report. Nephrol Dial Transplant. 1996;11:352–354
  21. Coppo P, Veyradier A, Durey MA, et al. Pathophysiology of thrombotic microangiopathies: Current understanding. Ann Med Interne (Paris). 2002;153:153–166
  22. Fukatsu A, Ito Y, Yuzawa Y, et al. A case of POEMS syndrome showing elevated serum interleukin 6 and abnormal expression of interleukin 6 in the kidney. Nephron. 1992;62:47–51
  23. Greiner T, Armitage JO, Gross TG. Atypical lymphoproliferative diseases. Hematology (Am Soc Hematol Educ Program). 2000;133–146Jan
  24. Leger-Ravet MB, Peuchmaur M, Devergne O, et al. Interleukin-6 gene expression in Castleman's disease. Blood. 1991;78:2923–2930
  25. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989;74:1360–1367
  26. Brandt SJ, Bodine DM, Dunbar CE, et al. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest. 1990;86:592–599
  27. Burke GW, Ciancio G, Cirocco R, et al. Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: Evidence of endothelin and cytokine involvement. Transplantation. 1999;68:1336–1342
  28. Litalien C, Proulx F, Mariscalco MM, et al. Circulating inflammatory cytokine levels in hemolytic uremic syndrome. Pediatr Nephrol. 1999;13:840–845
  29. Wada H, Kaneko T, Ohiwa M, et al. Plasma cytokine levels in thrombotic thrombocytopenic purpura. Am J Hematol. 1992;40:167–170
  30. Greer IA, Lyall F, Perera T, et al. Increased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: A mechanism for endothelial dysfunction?. Obstet Gynecol. 1994;84:937–940
  31. Esmon CT. Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillieres Best Pract Res Clin Haematol. 1999;12:343–359
  32. Nishi J, Arimura K, Utsunomiya A, et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol. 1999;104:482–485
  33. Nishi J, Maruyama I. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: Proposed pathomechanism of vascular proliferation in the affected lymph node. Leuk Lymphoma. 2000;38:387–394
  34. Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell–derived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104:100–106
  35. Shelat SG, Ai J, Zheng XL, et al. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. Semin Thromb Hemost. 2005;31:659–672

 Originally published online as doi:10.1053/j.ajkd.2008.08.026 on November 7, 2008.

PII: S0272-6386(08)01353-X

doi: 10.1053/j.ajkd.2008.08.026

American Journal of Kidney Diseases
Volume 53, Issue 3 , Pages 550-554 , March 2009

Article Tools

* Image Usage & Resolution